Aegros presents to Australia’s National Blood Authority
This video details the HaemaFrac® and the importance of this to the National Blood Authority including financial, environmental & to the security of Australia’s blood supply.
A Proud Day for Aegros As It Receives TGA GMP Approval
Aegros’ production facility, located in Macquarie Park Sydney where its innovative HaemaFrac® technology is housed, and where Aegros is making its Covid-19 hyperimmune product, today received its Good Manufacturing Process (GMP) accreditation from the Therapeutic Goods Administration (TGA). The milestone means Australia now officially has a new fractionator within its borders, adding capability, structural resilience, […]
Aegros Is Excited to Begin Covid-19 Hyperimmune Trial
Thanks to Aegros’ revolutionary HaemaFrac® technology, we have created a hyperimmune product from convalescent plasma to fight Covid-19, that is ready to begin clinical trial prior to being approved to take its place among the limited weapons doctors have to combat this pandemic virus. This is a massive step for Aegros. As a start-up company […]
The place of hyperimmunes in a Vaccine world
AEGROS AWARDED COLLABORATIVE AUSTRALIAN RESEARCH COUNCIL LINKAGE PROJECT (ARCLP) GRANT TO SUPPORT $1.8M PROJECT Hyperimmunes & Vaccines We are pleased to see the recent announcements suggesting several vaccines maybe available, hopefully, from March 2021. Hyperimmunes and vaccines work hand-in-glove. We require both of these treatment modalities to protect society from the ravages of a virus […]
AEGROS Awarded Collaborative Australian Research Council Linkage Project (ARCLP)
FOR IMMEDIATE RELEASE Sydney, Australia 25th February 2019 – The Board of Aegros is delighted to advise that the Australian Research Council (ARC) has awarded the prestigious ARCLP grant to Aegros and their academic collaborators the University of Queensland. The grant was awarded to develop new generation Smart Membranes for industrial applications of Aegros’ patented […]
